Elranatamab - CISMeF

Preferred Label : Elranatamab;

NCIt synonyms : BCMA-CD3 Bispecific Ab PF-06863135; Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135; B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135; BCMA x CD3 Bispecific Antibody PF-06863135; Elranatamab-bcmm;

NCIt definition : A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.;

UNII : L0HR9A577V;

CAS number : 2408850-14-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2408850-14-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Elrexfio;

Molecule name : PF-06863135; PF 06863135; RN 613; RN-613;

NCI Metathesaurus CUI : CL544825;

Origin ID

C146860;

UMLS CUI

C5667166;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tumor Necrosis Factor Receptor Superfamily Member 17 [NCIt concept]
is_component_of_chemotherapy_regimen
- Elranatamab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Details

Main resources

You can consult :